Navigation Links
Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity
Date:12/13/2007

Patients with FDA-defined Valvulopathy Permitted to Enroll in 2nd and 3rd

Pivotal Trials - Echocardiogram Screening Requirement Eliminated

SAN DIEGO, Dec. 13 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced the initiation of patient screening in the second and third Phase 3 pivotal trials evaluating the efficacy and safety of its lead drug candidate, lorcaserin hydrochloride, for weight management in overweight and obese patients. Known as BLOSSOM (Behavioral modification and Lorcaserin Second Study for Obesity Management) and BLOOM-DM (Behavioral modification and Lorcaserin for Overweight and Obesity Management in Diabetes Mellitus), these one-year, double-blind, randomized and placebo-controlled trials are expected to collectively enroll approximately 3,750 overweight and obese patients. Consistent with Arena's proposal, the Food and Drug Administration, or FDA, is allowing patients with FDA-defined valvulopathy to enroll in both BLOSSOM and BLOOM-DM. This is different from the design of the initial lorcaserin pivotal study known as BLOOM, in which echocardiography was used to screen for patients with FDA-defined valvulopathy and exclude those patients from enrolling in the trial. Instead, in BLOSSOM and BLOOM-DM, there are no such echocardiographically defined exclusion criteria, although serial echocardiograms will be obtained to extend the lorcaserin safety database. BLOOM, BLOSSOM and BLOOM-DM comprise the entire planned pivotal trial program for lorcaserin.

"Eliminating the requirement of screening echoes, and receiving permission from the FDA to expand the patient population of the lorcaserin pivotal trial program to include patients with FDA-defined valvulopathy, is a signifi
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Arena Pharmaceuticals to Present at the Bear Stearns 20th Annual Healthcare Conference
2. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review
3. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review
4. Arena Pharmaceuticals Selected to Join New NASDAQ NeuroInsights Neurotech Index
5. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Arena Pharmaceuticals to Report Third Quarter 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, October 17, 2007
7. Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results
8. Arena Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Arena Pharmaceuticals Appoints Phillip M. Schneider and Randall E. Woods to Board of Directors
10. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
11. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... New York, NY (PRWEB) January 14, 2014 ... coverage of Alliqua, Inc. (OTCQB: ALQA). Alliqua is an ... products to serve the wound care market. , Free ... Alliqua was restructured with a seasoned management team and ...
(Date:1/14/2014)... BETHESDA, Md. , Jan. 14, 2014 ... two institutes from the National Institutes of Health (NIH) ... safer, more effective treatments to patients on a faster ... Advancing Translational Sciences (NCATS) and the National Eye Institute ...
(Date:1/14/2014)... In recent years, growing suspicion about the pharmaceutical ... and promotion has led to unprecedented levels of public ... about the insidious impact of commercialization of research, has ... the world’s biggest pharmas for illegal marketing activities, allegations ...
(Date:1/14/2014)... MD (PRWEB) January 14, 2014 ... to developing innovative information technology solutions for patients, ... health care stakeholders, announced today the signing of ... US Food and Drug Administration (FDA). This ...
Breaking Biology Technology:EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2
... Biomatrica, the leader in room,temperature biological sample stabilization, announced ... President of Sales and Marketing.,Biomatrica,s interim Vice President of ... of the company and will continue to serve as,an ... brings fourteen years of sales and marketing experience in,the ...
... operations during the first ... ... in US dollars, QUEBEC CITY, May 6 /PRNewswire-FirstCall/ - Atrium Innovations ... for health and nutrition industries, announced today,his financial results for the first ...
... 5 NeoGenomics, Inc. (OTC,Bulletin Board: NGNM) announced today that ... Wednesday, May 7, 2008., The Company has scheduled ... on May 7, 2008, at 11:00 AM EDT. Interested ... least,five minutes prior to the call. A replay of ...
Cached Biology Technology:Trisha Dowling Joins Biomatrica as Vice President, Sales and Marketing 2Atrium shows a strong financial performance for its first quarter 2Atrium shows a strong financial performance for its first quarter 3Atrium shows a strong financial performance for its first quarter 4Atrium shows a strong financial performance for its first quarter 5NeoGenomics Schedules Its Q1 2008 Earnings Release for May 7, 2008 2
(Date:4/24/2014)... brain infection caused by fungus could now be treated in ... University of Liverpool scientists. , Cryptococcus a ... relatively neglected in medical research. They are found in ... East Asia and mainly affect people with weakened immune systems. ... The University research team has tested the effects of the ...
(Date:4/24/2014)... largest river turtle in North America, weighing in at ... Now researchers from Florida and the University of Vermont ... but three. , Examining museum specimens and wild turtles, ... reptile. , Once heavily hunted for turtle meat ... Soup in the 1960s the riverine populations have ...
(Date:4/23/2014)... allergies and other chronic inflammatory disorders among people of ... their reduced exposure to the microbes that thrive in ... The article, published in the journal Clinical & ... centers who have less access to green spaces may ... caused by immune system dysfunction. , When our immune ...
Breaking Biology News(10 mins):Treatment for deadly yeast disease reduced to 3 days 2Two new US turtle species described 2Two new US turtle species described 3Rural microbes could boost city dwellers' health 2Rural microbes could boost city dwellers' health 3
... Brookhaven National Laboratory, the New York Structural Biology ... atomic crystal structure and functional mechanism of an ... as drugs, industrial chemicals, and toxic compounds from ... help scientists understand how these compounds are eliminated ...
... improve on milk, but animal scientists at the University ... transgenic goats, which carry the gene for an antibacterial ... bacteria in young goats and pigs that were fed ... one day lead to milk that protects infants and ...
... are preparing to stockpile vaccines against H5N1, the strain ... next flu pandemic. But will these vaccines remain effective ... the July 15 issue of The Journal of Infectious ... PhD, Robert G. Webster, PhD, and coworkers at St. ...
Cached Biology News:Scientists take 'snapshots' of enzyme action 2Transgenic goat's milk offers hope for tackling children's intestinal disease 2Transgenic goat's milk offers hope for tackling children's intestinal disease 3Experimental vaccine protects lab animals against several strains of H5N1 2
... through the extracellular matrix (ECM) is an ... cells initiate invasion by adhering to and ... Proteolytic enzymes, such as MMP collagenases, dissolve ... membrane) surrounding the blood vessels to allow ...
... This CLS number is ... to easily match Cornings product ... yet, please order under the ... contact customer service for assistance. ...
Kit containing MACS equipment and reagents for immunopurification of proteins....
... of poor quality running into billions ... are under increasing pressure to reduce ... the microscopic distribution of ingredients is ... such as dissolution, stability, bio-availability and ...
Biology Products: